Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ALLIANCE FIB | AFOP | 14.83% |
| A M R CP | AAMRQ | 7.91% |
| OLD SECOND B | OSBC | 6.73% |
| SANTARUS INC | SNTS | 6.23% |
| JAZZ PHARMAC | JAZZ | 6.17% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We reiterate our recommendation for Patterson Companies Inc. ( PDCO - Analyst Report ) at Neutral. Its second quarter fiscal 2013 adjusted earnings of 44 cents per share (up 2.3% year-over-year) missed the Zacks Consensus Estimate of 49 cents.
Sales for the fiscal second quarter edged up 1% year over year to $867.2 million, trailing the Zacks Consensus Estimate of $894 million. Sales were adversely affected by soft dental equipment sales (including chairs and lighting), partially offset by strong technology equipment sales. However, the Veterinary business contributed significantly to total sales.
Revenues from the core Patterson Dental remained approximately flat year over year at $549.1 million. Within Patterson Dental, sales of consumable and printed products inched up 1% to $315.4 million in the quarter. Sales from the equipment and software offerings unexpectedly dropped 3.2% to $169.3 million. Higher demand for the CEREC system, which has been incorporated with the latest Omnicam camera, was constrained by limited product availability. This offset higher technology products sales. Other services and products grew 1.6% year over year to $64.5 million.
Revenues from the Webster Veterinary segment grew 6.8% to $184.4 million. Internally-generated sales jumped 13% in the reported quarter. Revenues from Patterson Medical segment remained flat year over year at $133.7 million due to lower equipment sales. Surgical Synergies, the company acquired by Patterson in April 2012, contributed 1% to the sales growth of this business segment. This division’s equipment franchise continues to be adversely impacted by the uncertainties related to the U.S. health care system.
For fiscal 2013, Patterson lowered its earnings forecast to the range of $2.00 to $2.06 per share from the earlier range of $2.10 to $2.16 per share due to the company’s disappointing second-quarter results as well as the persisting macroeconomic uncertainties.
Patterson provides a wide range of consumables, equipment and software, and value-added services to its customers. Patterson competes head-to-head with Henry Schein Inc. ( HSIC - Snapshot Report ) in the dental market.
Patterson Dental is the company’s largest business segment and one of the two largest distributors of dental products in North America. The recent acquisition of Iowa Dental Supply, LLC (IDS), a full service distributor of dental products, will likely boost Patterson Dental’s foothold in the mid-western U.S. market and provide a competitive edge as well.
Moreover, the alliance with Sirona Dental Systems Inc. ( SIRO - Snapshot Report ) , a leading dental technologies company, further bolsters Patterson Dental’s leading position in the North American dental distribution business. The Omnicam camera for the CEREC system, developed by Sirona and to be distributed by Patterson, is the latest growth driver for this product line.
However, the company remains affected by tough macroeconomic issues in North America and international markets. It is also facing internal operational shortcomings, which need to be addressed. The stock carries a short-term Zacks #4 Rank (Sell).
Read the full Snapshot Report on HSIC
Read the full Analyst Report on PDCO
Read the full Snapshot Report on SIRO